The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | HIMALAYA trial: Asian subgroup results
Stephen L. Chan, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), Chinese University of Hong Kong, Hong Kong, talks on the Phase III HIMALAYA trial (NCT03298451), investigating durvalumab and tremelimumab in the first-line setting for patients with hepatocellular carcinoma (HCC). Patients received either durvalumab monotherapy, durvalumab plus tremelimumab, or sorafenib monotherapy. Dr Chan discusses results from the Asian subgroup population of the trial. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
